A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Tipranavir (Primary) ; Lopinavir/ritonavir; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 12 Nov 2008 Results of metabolic substudy published in AIDS, according to 1133716.
- 29 Sep 2006 The expected completion date for this trial is now 1 Mar 2007.
- 16 Nov 2005 New trial record.